Medtronic Launches MiniMed Go™ Smart MDI System to Transform Diabetes Management in Europe

Medtronic Launches Innovative Diabetes Management Tool in Europe

Medtronic Plc has unveiled the MiniMed Go™ Smart MDI system alongside the Simplera™ sensor, marking a significant stride in diabetes care management. Launched on February 25, 2026, this system represents a pioneering approach by integrating data from the InPen™ smart insulin pen and Simplera™ sensor into a singular mobile application. Designed specifically for individuals utilizing multiple daily injections (MDI) to control their diabetes, the MiniMed Go™ offers users a seamless interface that not only simplifies but enhances diabetes management. The gradual rollout throughout Europe is set to begin this month, highlighting Medtronic's commitment to improving patient outcomes through innovative technologies.

The MiniMed Go™ system stands out from traditional insulin pens by providing real-time personalized insights, actionable dose alerts, and a sophisticated dose calculator, all within a user-friendly smartphone app. Aimed at addressing gaps in diabetes management, the system helps mitigate the risks associated with missed insulin doses—a common issue that can lead to poor glycemic control. Notably, research indicates that neglecting two doses weekly could elevate a patient's HbA1C level by as much as 0.4%, increasing the likelihood of severe complications. By proactively urging users to respond to missed doses, Medtronic's new tool empowers individuals to stay on track with their insulin regimen and achieve better health outcomes.

The efficacy of the MiniMed Go™ is backed by data from earlier Smart MDI systems, which showed that users who reacted to over 75% of missed dose alerts within an hour achieved significant improvements in their Time in Range (TIR). Specifically, these users recorded a TIR of 67.2%, surpassing the cohort average of 55.7%. Moreover, through timely alerts regarding elevated blood sugar, TIR figures reached as high as 71.5%. Que Dallara, Executive Vice President and President of Medtronic Diabetes, underscores the critical role of real-time alerts in enhancing clinical outcomes for MDI users, asserting that the MiniMed Go™ system is a game-changer in diabetes management.

In addition to its groundbreaking features, the MiniMed Go™ system underscores Medtronic's ongoing dedication to transforming diabetes care through technology. By focusing on user engagement and real-time interventions, the company positions itself as a leader in healthcare innovation. This development aligns with broader trends in the industry, where digital health solutions are increasingly integral to effective disease management and patient empowerment.

Medtronic's introduction of the MiniMed Go™ also elevates the conversation about the intersection of technology and healthcare, signaling a new era in diabetes management. As the system becomes available across Europe, stakeholders in the healthcare community eagerly anticipate its impact on clinical practices and patient experiences in managing diabetes.